Dr. James Kim, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 321
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35.138389
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mh St Elizabeth Youngstown Hospital Youngstown, OH
- Hmhp St Elizabeth Boardman Health Center Boardman, OH
- Mh St Joseph Warren Hospital Warren, OH
- Surgical Hospital at Southwoods Youngstown, OH
Medical groups
- Mercy Health Physicians Youngstown Specialty Care LLC (472 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 321
- Services billed
- 1,088
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 460 | 137 |
| Established patient office or other outpatient visit, 20-29 minutes | 127 | 100 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 83 | 46 |
| New patient office or other outpatient visit, 45-59 minutes | 62 | 62 |
| Established patient office or other outpatient visit, 40-54 minutes | 47 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 43 | 43 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 40 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Youngstown, OH | 245 |
| Prochlorperazine Maleate Other prescribers in Youngstown, OH | 98 |
| Tamoxifen Citrate Other prescribers in Youngstown, OH | 61 |
| Letrozole Other prescribers in Youngstown, OH | 52 |
| Ondansetron Hcl Other prescribers in Youngstown, OH | 51 |
| Prednisone Other prescribers in Youngstown, OH | 51 |
| Ibrance (palbociclib) | 44 |
| Duloxetine Hcl Other prescribers in Youngstown, OH | 40 |
| Hydroxyurea Other prescribers in Youngstown, OH | 40 |
| Ondansetron Odt (ondansetron) Other prescribers in Youngstown, OH | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 7 payments worth $607 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $145 |
|---|---|
| Jazz Pharmaceuticals Inc. | $126 |
| Janssen Biotech, Inc. | $110 |
| Beone Medicines USA, Inc. | $110 |
| Seagen Inc. | $99.99 |
| 180 Medical, Inc. | $15.72 |
| Food and Beverage | $507 |
|---|---|
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Seagen Inc. Oct 29, 2025 | Education in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $43,701 in research payments for these studies, mostly to the institutions running them.
- SPI-GCF-104
Spectrum Pharmaceuticals Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.